

Cervical cancer prevention and HPV vaccines

Two vaccines are now available to prevent infection by the strains of human papillomavirus (HPV) that cause 70% of all cervical cancer cases. GAVI supports the introduction of HPV vaccines in eligible countries. The type of support provided by GAVI depends on the level of demonstrated ability in a country to deliver vaccines to young adolescent girls.

Demonstrated ability is defined as prior experience in delivering multi-dose vaccines to at least 50% of a single cohort (e.g., all 10 year old girls or all girls in primary grade 4) within the target population of 9-13 year old girls in a typical district of the Expanded Programme on Immunisation (EPI).

Countries that **have demonstrated** the ability to deliver HPV vaccine to young adolescent girls may apply for GAVI support for **national introduction using the** standard NVS application form.

Countries that **have not yet demonstrated** the ability to deliver HPV vaccine to adolescent girls may apply for GAVI support to implement a two-year HPV vaccination **demonstration programme**. The two-year programme will assist countries to prepare for a decision on national introduction, and if affirmative, to submit an application to GAVI for national use.

Information about GAVI's 2014 application round (including HPV application specific requirements for both national introduction and the vaccination demonstration programme) can be found at: http://www.gavialliance.org/support/apply/

The primary objectives of the HPV vaccination demonstration programme:

- Support countries to "learn by doing", through assessing potential successful HPV vaccine delivery strategies in order to generate evidence for decision-making on national introduction with GAVI support; and
- Assess the feasibility of integrating selected adolescent health interventions, appropriate to the age group targeted for HPV vaccine (9-13 year old girls), with the delivery of HPV vaccine; and
- Encourage integration of primary prevention through HPV vaccination in a **national cervical** cancer prevention and control strategy.

HPV vaccination demonstration programme process:

